Header Forschung

Nuclear Medicine

Tracer principle is the basis of radionuclide application including molecular imaging and therapy which means that the very low amount of radionuclides doesn’t cause allergic or pharmacological reactions. Therefore, nuclear medicine is safe, highly sensitive, specific and smart. Radiotracers serve to visualize physiology and specific changes in blood flow, metabolism as well as transporter or receptor state depending on disease and its genesis. Clinical applications of Glucose (FDG-)PET characterise unclear lesions via metabolism, define tumor extension for adequate therapy and monitor the influence of various treatment modalities on tumor viability. The combination of diagnostic and therapeutic approaches is called “theranostics” – radiotracer tumor accumulation for imaging and therapy. The combination of internal and external radiotherapy (CIERT) is a promising approach comparable to the combination of chemotherapy and irradiation therapy. Nuclear medicine provides cancer therapy with special focus on thyroid carcinoma for more than 70 years while more recent developments address neuroendocrine tumors and prostate cancer.

In addition local expertise focusses on micro- and biodosimetry of unsealed radionuclides (including Auger electrons and alpha-emitters) with multiple radiobiological tests and the modification of DNA damage by various medications.

The diagnostic imaging with Positron emission tomography/computed tomography (PET/CT) using the radiopharmaceutical Ga-68-DOTATOC in a patient suffering from a neuroendocrine tumor (NET) indicated multiple liver, bone and lymph node metastases (A). After a Peptide Receptor Radiotherapy (PRRT) with Y-90-DOTATOC was performed the control PET scan three months later revealed a complete functional response (B). @Prof. Kotzerke, Klinik und Poliklinik für Nuklearmedizin

1. Butof R, Hofheinz F, Zophel K et al. Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019; 60: 192-198.

2. Hoberuck S, Lock S, Winzer R et al. [(68)Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI research 2020; 10: 135.

3. Hoberuck S, Wunderlich G, Michler E et al. Dual-time-point (64) Cu-PSMA-617-PET/CT in patients suffering from prostate cancer. Journal of labelled compounds & radiopharmaceuticals 2019; 62: 523-532.

4. Kotzerke J, Runge R, Gotze P et al. [Radio- and photosensitization of plasmid DNA by DNA binding ligand propidium iodide: Investigation of Auger electron induction and detection of Cherenkov-emission]. Nuklearmedizin Nuclear medicine 2019; 58: 319-327.

5. Reissig F, Wunderlich G, Runge R et al. The effect of hypoxia on the induction of strand breaks in plasmid DNA by alpha-, beta- and Auger electron-emitters (223)Ra, (188)Re, (99m)Tc and DNA-binding (99m)Tc-labeled pyrene. Nuclear medicine and biology 2020; 80-81: 65-70.